The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
about
Trial watch: Immune checkpoint blockers for cancer therapy.Review of cancer treatment with immune checkpoint inhibitors : Current concepts, expectations, limitations and pitfalls.Efferocytosis of dying cells differentially modulate immunological outcomes in tumor microenvironment.Myopenia and precision (P4) medicine.A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy.
P2860
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
@en
type
label
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
@en
prefLabel
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
@en
P2093
P2860
P356
P1433
P1476
The future of immune checkpoint cancer therapy after PD-1 and CTLA-4.
@en
P2093
Andrew W Hahn
David M Gill
Neeraj Agarwal
Sumanta K Pal
P2860
P304
P356
10.2217/IMT-2017-0024
P577
2017-06-01T00:00:00Z